Drug intelligence / Profile preview

II-25

Development stage: Discontinued
Lead developer: University of the Pacific
Modality: Small Molecules

Overview

II-25 is a novel piperazinylpyrimidine derivative designed to target the human kinome. Developed by researchers at the University of the Pacific, II-25 was synthesized as part of a series of compounds combining a piperazinylpyrimidine core with kinase-privileged fragments. In preclinical evaluations against the NCI-60 panel of cancer cell lines, II-25 demonstrated very weak antiproliferative activity, with a mean GI50 of greater than 100 μM.

Targets

HIV-1 reverse transcriptase RNase H domain

Beyond the preview

Go deeper on II-25.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on II-25.

Explore the full profile